Carthamus tinctorius Enhances Antitumor Activity of Dendritic Cell Vaccines
Author Information
Author(s): Chang Jia-Ming, Hung Le-Mei, Chyan Yau-Jan, Cheng Chun-Ming, Wu Rey-Yuh
Primary Institution: Development Center for Biotechnology, Xizhi City, Taipei County, Taiwan
Hypothesis
Does Carthamus tinctorius improve the effectiveness of dendritic cell-based vaccines in cancer treatment?
Conclusion
Carthamus tinctorius enhances the antitumor activity of dendritic cell vaccines by promoting Th1 cytokine responses and increasing cytotoxic T lymphocytes.
Supporting Evidence
- Carthamus tinctorius extract increased the secretion of Th1 cytokines like IFN-γ and IL-10.
- DCs treated with Carthamus tinctorius showed enhanced maturation and expression of immunological markers.
- CT-treated DC vaccines reduced tumor weight by 15.3% compared to untreated DC vaccines.
- CT extract polarized cytokine secretion toward the Th1 pathway.
- More cytotoxic T lymphocytes were generated in response to CT-treated DC vaccines.
Takeaway
Carthamus tinctorius, a plant used in traditional medicine, helps cancer vaccines work better by boosting the immune system's response.
Methodology
The study involved treating mouse splenic T lymphocytes and dendritic cells with Carthamus tinctorius extract and assessing cytokine secretion and tumor response in vivo.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
BALB/c female mice, aged 4–6 weeks.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website